Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer

Michihiko Kuwano, Tomohiro Shibata, Kosuke Watari, Mayumi Ono

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Y-box binding protein-1 (YBX1), a multifunctional oncoprotein containing an evolutionarily conserved cold shock domain, dysregulates a wide range of genes involved in cell proliferation and survival, drug resistance, and chromatin destabilization by cancer. Expression of a multidrug resistance-associated ATP binding cassette transporter gene, ABCB1, as well as growth factor receptor genes, EGFR and HER2/ErbB2, was initially discovered to be transcriptionally activated by YBX1 in cancer cells. Expression of other drug resistance-related genes, MVP/LRP, TOP2A, CD44, CD49f, BCL2, MYC, and androgen receptor (AR), is also transcriptionally activated by YBX1, consistently indicating that YBX1 is involved in tumor drug resistance. Furthermore, there is strong evidence to support that nuclear localization and/or overexpression of YBX1 can predict poor outcomes in patients with more than 20 different tumor types. YBX1 is phosphorylated by kinases, including AKT, p70S6K, and p90RSK, and translocated into the nucleus to promote the transcription of resistance- and malignancy-related genes. Phosphorylated YBX1, therefore, plays a crucial role as a potent transcription factor in cancer. Herein, a novel anticancer therapeutic strategy is presented by targeting activated YBX1 to overcome drug resistance and malignant progression.

Original languageEnglish
Pages (from-to)1536-1543
Number of pages8
JournalCancer Science
Volume110
Issue number5
DOIs
Publication statusPublished - May 1 2019

Fingerprint

Y-Box-Binding Protein 1
Drug Resistance
Pharmaceutical Preparations
Neoplasms
Therapeutics
Genes
erbB-2 Genes
70-kDa Ribosomal Protein S6 Kinases
erbB-1 Genes
ATP-Binding Cassette Transporters
Growth Factor Receptors
Oncogene Proteins
Androgen Receptors
Multiple Drug Resistance
Chromatin
Shock
Cell Survival
Transcription Factors
Phosphotransferases
Cell Proliferation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer. / Kuwano, Michihiko; Shibata, Tomohiro; Watari, Kosuke; Ono, Mayumi.

In: Cancer Science, Vol. 110, No. 5, 01.05.2019, p. 1536-1543.

Research output: Contribution to journalReview article

Kuwano, Michihiko ; Shibata, Tomohiro ; Watari, Kosuke ; Ono, Mayumi. / Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer. In: Cancer Science. 2019 ; Vol. 110, No. 5. pp. 1536-1543.
@article{0245046fcf75447f8aa8b688533fef7d,
title = "Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer",
abstract = "Y-box binding protein-1 (YBX1), a multifunctional oncoprotein containing an evolutionarily conserved cold shock domain, dysregulates a wide range of genes involved in cell proliferation and survival, drug resistance, and chromatin destabilization by cancer. Expression of a multidrug resistance-associated ATP binding cassette transporter gene, ABCB1, as well as growth factor receptor genes, EGFR and HER2/ErbB2, was initially discovered to be transcriptionally activated by YBX1 in cancer cells. Expression of other drug resistance-related genes, MVP/LRP, TOP2A, CD44, CD49f, BCL2, MYC, and androgen receptor (AR), is also transcriptionally activated by YBX1, consistently indicating that YBX1 is involved in tumor drug resistance. Furthermore, there is strong evidence to support that nuclear localization and/or overexpression of YBX1 can predict poor outcomes in patients with more than 20 different tumor types. YBX1 is phosphorylated by kinases, including AKT, p70S6K, and p90RSK, and translocated into the nucleus to promote the transcription of resistance- and malignancy-related genes. Phosphorylated YBX1, therefore, plays a crucial role as a potent transcription factor in cancer. Herein, a novel anticancer therapeutic strategy is presented by targeting activated YBX1 to overcome drug resistance and malignant progression.",
author = "Michihiko Kuwano and Tomohiro Shibata and Kosuke Watari and Mayumi Ono",
year = "2019",
month = "5",
day = "1",
doi = "10.1111/cas.14006",
language = "English",
volume = "110",
pages = "1536--1543",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer

AU - Kuwano, Michihiko

AU - Shibata, Tomohiro

AU - Watari, Kosuke

AU - Ono, Mayumi

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Y-box binding protein-1 (YBX1), a multifunctional oncoprotein containing an evolutionarily conserved cold shock domain, dysregulates a wide range of genes involved in cell proliferation and survival, drug resistance, and chromatin destabilization by cancer. Expression of a multidrug resistance-associated ATP binding cassette transporter gene, ABCB1, as well as growth factor receptor genes, EGFR and HER2/ErbB2, was initially discovered to be transcriptionally activated by YBX1 in cancer cells. Expression of other drug resistance-related genes, MVP/LRP, TOP2A, CD44, CD49f, BCL2, MYC, and androgen receptor (AR), is also transcriptionally activated by YBX1, consistently indicating that YBX1 is involved in tumor drug resistance. Furthermore, there is strong evidence to support that nuclear localization and/or overexpression of YBX1 can predict poor outcomes in patients with more than 20 different tumor types. YBX1 is phosphorylated by kinases, including AKT, p70S6K, and p90RSK, and translocated into the nucleus to promote the transcription of resistance- and malignancy-related genes. Phosphorylated YBX1, therefore, plays a crucial role as a potent transcription factor in cancer. Herein, a novel anticancer therapeutic strategy is presented by targeting activated YBX1 to overcome drug resistance and malignant progression.

AB - Y-box binding protein-1 (YBX1), a multifunctional oncoprotein containing an evolutionarily conserved cold shock domain, dysregulates a wide range of genes involved in cell proliferation and survival, drug resistance, and chromatin destabilization by cancer. Expression of a multidrug resistance-associated ATP binding cassette transporter gene, ABCB1, as well as growth factor receptor genes, EGFR and HER2/ErbB2, was initially discovered to be transcriptionally activated by YBX1 in cancer cells. Expression of other drug resistance-related genes, MVP/LRP, TOP2A, CD44, CD49f, BCL2, MYC, and androgen receptor (AR), is also transcriptionally activated by YBX1, consistently indicating that YBX1 is involved in tumor drug resistance. Furthermore, there is strong evidence to support that nuclear localization and/or overexpression of YBX1 can predict poor outcomes in patients with more than 20 different tumor types. YBX1 is phosphorylated by kinases, including AKT, p70S6K, and p90RSK, and translocated into the nucleus to promote the transcription of resistance- and malignancy-related genes. Phosphorylated YBX1, therefore, plays a crucial role as a potent transcription factor in cancer. Herein, a novel anticancer therapeutic strategy is presented by targeting activated YBX1 to overcome drug resistance and malignant progression.

UR - http://www.scopus.com/inward/record.url?scp=85065254461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065254461&partnerID=8YFLogxK

U2 - 10.1111/cas.14006

DO - 10.1111/cas.14006

M3 - Review article

C2 - 30903644

AN - SCOPUS:85065254461

VL - 110

SP - 1536

EP - 1543

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 5

ER -